Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCT-901 in Advanced Solid Tumors
NCT04972981Phase 1Completed
- Sponsor
- ADC Therapeutics
- Start
- Sep 2021
- Primary completion
- Sep 2024
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label trial of olintatug tesirine in solid tumor (advanced stage), cholangiocarcinoma (CCA), ovarian cancer and 4 more (2 arms), sponsored by ADC Therapeutics. Primary endpoints: Number of Participants with Adverse Events at 2.5 years, Number of Participants Who Experience a Dose Limiting Toxicity at 21 days and 2 more. Started Sep 2021; status: completed.
02
Drugs
olintatug tesirine
03
Conditions
solid tumor (advanced stage)cholangiocarcinoma (CCA)ovarian cancerfallopian tube cancer (PFTC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04972981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04972981.